Pro 001
Alternative Names: Pro-001Latest Information Update: 28 Jul 2023
At a glance
- Originator PSR Biopharma
- Developer Protheragen; PSR Biopharma
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Ovarian cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in China (Parenteral)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 28 Jul 2023 No recent reports of development identified for research development in Acute-myeloid-leukaemia in China (Parenteral)